Artemis Medicare Q1 FY27 Call: Date, Dividend, Fundraise

Why this update matters for investors

Artemis Medicare Services Limited has lined up a set of near-term corporate events that investors typically track closely in a hospital operator: quarterly results, an earnings discussion with analysts, and a final dividend process. The company has scheduled a Q1 FY27 earnings conference call on August 4, 2026, to discuss operational and financial performance for the quarter ended June 30, 2026. Separately, it has also indicated that its board will consider and approve the unaudited financial results at a board meeting on August 3, 2026.

Alongside the results cycle, the company has fixed July 10, 2026 as the record date for a final dividend of Rs 0.45 per share. Artemis Medicare has also disclosed that shareholders approved a special resolution to raise funds through equity shares and other eligible securities, with 98.68% of votes cast in favour.

Q1 FY27 earnings call: schedule and host

The earnings conference call is scheduled for Tuesday, August 4, 2026 at 11:00 AM IST. The call is being hosted by Anand Rathi Research. The company said the discussion is aimed at investors and analysts and is being held pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For market participants, the call is typically the first opportunity after the board meeting for management commentary on quarterly trends, occupancy, payer mix, and any near-term capex or fund-raising timelines.

Dial-in details for investors and analysts

Participants can join the call using the following access numbers disclosed by the company.

For coordination, the company has provided the contact details of Himanshu Binani: Office No (022) 6626 6712 and Mobile 7381039698.

Board meeting on August 3 and trading window closure

Artemis Medicare Services Limited will hold a board meeting on August 3, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company has also stated that the trading window for its securities was closed from July 1, 2026 and will remain closed until August 5, 2026.

The sequencing implies that financial results are expected to be approved on August 3, followed by an investor call the next day. This structure is common for listed companies, where the board approves results first and management then addresses analyst questions on the public disclosures.

Final dividend: record date and amount

The company has indicated a final dividend of Rs 0.45 per share, with July 10, 2026 fixed as the record date. Investors holding shares as of the record date are typically eligible for the dividend, subject to the company’s stated process and applicable rules.

As of July 31, 2026, the company’s dividend yield was disclosed at 0.15%, reflecting a relatively modest payout compared with the market price levels indicated in the same update.

Fund-raise: shareholder approval with 98.68% votes in favour

Artemis Medicare Services Ltd shareholders have approved a special resolution to raise funds via equity shares and other eligible securities. The company said the resolution passed with 98.68% of votes cast in favour, with support from promoters and public shareholders.

In a separate disclosure, Artemis Medicare has also referenced board approval to raise up to INR 700 crore, subject to shareholder approval once assets are finalised. With shareholder approval now disclosed for a broader fund-raise resolution, investors will track subsequent details such as instrument type, pricing, tranches, and any linked capex or expansion milestones, if and when the company announces them.

Recent financial performance: key disclosed numbers

In its disclosed financial highlights for Q4 FY26, the company reported revenue from operations of Rs 27,923 lakh (Rs 279.23 crore), compared with Rs 23,990 lakh (Rs 239.90 crore) in the comparable period. It also reported EBITDA of Rs 5,938 lakh (Rs 59.38 crore) versus Rs 4,824 lakh (Rs 48.24 crore), and PAT of Rs 3,028 lakh (Rs 30.28 crore) versus Rs 2,292 lakh (Rs 22.92 crore).

For FY26, revenue from operations was reported at Rs 1,08,124 lakh (Rs 1,081.24 crore) compared with Rs 93,692 lakh (Rs 936.92 crore). FY26 EBITDA was Rs 21,801 lakh (Rs 218.01 crore) versus Rs 18,478 lakh (Rs 184.78 crore), while FY26 PAT was Rs 10,372 lakh (Rs 103.72 crore) versus Rs 8,218 lakh (Rs 82.18 crore).

The company has also disclosed Q1 FY26 consolidated metrics in another update: net revenue from operations of Rs 2,550 million (Rs 255.0 crore), EBITDA of Rs 483 million (Rs 48.3 crore), and net profit of Rs 212 million (Rs 21.2 crore). Separately, one line in the provided information mentions consolidated revenue growth to ₹25,496.09 crore for Q1 FY26; this figure is presented alongside other disclosures that cite quarterly net revenue of about Rs 255 crore for the same period.

Stock snapshot and shareholding details

As of July 31, 2026, Artemis Medicare Services Ltd was reported at Rs 298.50, down Rs 3.65 (1.21%) on the day. The disclosed market capitalisation was about Rs 4,792.72 crore. Valuation metrics shared in the same update included a PE (TTM) of 45.32 and a price-to-book ratio of 5.51.

The company trades on NSE under ARTEMISMED and on BSE under code 542919. The disclosed promoter holding is 58.39%, with public shareholding at 41.61%, including mutual funds at 1.30% and foreign institutional investors at 12.29%.

Key facts at a glance

What investors will watch next

The immediate focus is on the company’s unaudited Q1 FY27 results for the quarter ended June 30, 2026, expected to be approved on August 3, followed by management commentary on August 4. Investors will also track whether the company provides additional clarity on the proposed fund-raise structure and timing, given the disclosed shareholder approval and the reference to raising up to INR 700 crore.

Near term, the next confirmed milestones are the board meeting, the earnings conference call, and any follow-up filings that typically accompany quarterly results and capital-raising plans.